



Asia Pacific
Region of Opportunities

27 to 30 October 2009 Melbourne Convention and Exhibition Centre



www.ausbiotech2009.com.au



AUSBIOTECH 2009 PROGRAM*

TUESDAY 27 OCTOBER

8:00am – 7:00pm	Delegate Registration Desk Open <i>Concourse Melbourne Exhibition Centre</i>
9:30am – 4:00pm	AUSBIOTECH AUSTRALASIAN LIFE SCIENCES INVESTMENT SUMMIT By Invitation Only <i>Melbourne Convention Centre</i> Sponsored by Victorian Government, Austrade, ABN AMRO and Blueprint Life Science Group
3:30pm – 5:00pm	Networking High Tea with Exhibitors <i>Melbourne Exhibition Centre – Exhibition Hall</i>
9:30am – 5:00pm	SATELLITE EVENTS <i>Melbourne Convention Centre</i>
5:00pm – 5:30pm	Coaches to Government House depart Melbourne Convention Centre, Porte Cochere Main Entrance, Convention Centre Place, opposite Hilton South Wharf Hotel
6:00pm – 8:00pm	AUSBIOTECH 2009 WELCOME RECEPTION Professor David de Kretser, Governor of Victoria and Dr Deborah Rathjen, Chair, AusBiotech Ltd <i>Government House</i> Sponsored by Victorian Government
From 8:00pm	Coaches depart Government House to return delegates to the Melbourne Convention Centre

WEDNESDAY 28 OCTOBER

9:00am – 11:00am <i>Melbourne Convention Centre – Plenary Hall 3</i>	OPENING OF AUSBIOTECH 2009 <i>Melbourne Convention Centre – Plenary Hall 3</i> AWARD PRESENTATIONS - AusBiotech 2009 Excellence Awards – presented by Dr Deborah Rathjen, Chair, AusBiotech Ltd - Sponsored by Roche - AusBiotech–GSK Student Awards – presented by Dr Ashley Bates, Head of R&D Alliances Australia/NZ, GlaxoSmithKline - Sponsored by GlaxoSmithKline PLENARY 1 - Presentation title to be confirmed Dr Ganesh Kishore, CEO, Malaysian Life Sciences Capital Fund, Burrill and Company / Malaysian Technology Development Corporation, United States PLENARY 2 - Presentation title to be confirmed Dr John Diekman, Managing Director, Sam Ventures, United States
11:00am – 11:30am	Morning Tea BioIndustry Exhibition Hall

<p>11:30am – 1:00pm</p> <p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p style="text-align: center;">MEDTECH</p> <p>Global Opportunities - AusBiotech / Austrade working together</p> <p>AusBiotech has been selected as the lead organisation to establish an Australian Medical Device Manufacturers cluster, one of the eight successful clusters under the Austrade managed Global Opportunities program (GO). This pilot program aims to help Australian medtech companies to pursue export opportunities in the North American healthcare market, to targeting supply chains supplying medical devices to the government and non-government healthcare sectors</p> <p>Chair: Mr Glenn Cross, Chief Operating Officer, AusBiotech Ltd</p> <p>Speakers: Ms Janelle Casey, Industry Team Leader Health, Biotechnology and Wellbeing, Austrade</p> <p>Mr David Radford, Chief Executive Officer, Nanosonics</p> <p>Mr John Kelly, Chief Operating Officer, Polartechnics</p>	<p style="text-align: center;">HUMAN HEALTH</p> <p>Biopharmaceuticals in a post Global Financial Crisis world</p> <p>In the short term, the GFC has stifled funding for early stage biotech. As the market recovers, proposed changes to the US healthcare system could completely transform the biotech-pharma value chain and deal-making drivers. Meanwhile how will pharma address its looming patent cliff and other threats?</p> <p>Chair and Speaker: Mr Peter Molloy, President, Aquarius Consulting</p> <p>Speakers: Professor Susan Pond</p> <p>Dr Jeremy Levin, Senior Vice President, Strategic Transactions Group, Bristol Myers Squibb</p>	<p style="text-align: center;">AG / INDUSTRIAL / FOOD</p> <p>Advancing the Industrial Biotech Revolution</p> <p>This session will explore the issues of synthetic biology tools and how they are addressing the needs for renewable fuels and chemicals. The commercialization roadmap will be discussed, contrasting partnership approaches with the petrochemical industry. In closing, funding strategies will be considered in the context of feeding the industrial biotechnology revolution.</p> <p>Chair: Damien Perriman, Vice President Business Development, Verdezyne, Inc., United States</p> <p>Speakers: Professor Lars Nielsen Chair and Professor in Biological Engineering Australian Institute for Bioengineering and Nanotechnology (AIBN) (accepted)</p> <p>Mr David Theriault Business Development Leader Emerging Technology, The Dow Chemical Company</p> <p>Mr Karl Kelly, CEO, Stirius Inc</p>	<p style="text-align: center;">INVESTMENT / BUSINESS</p> <p>Wish list for investors – what fund managers are looking for?</p> <p>The GFC has changed the world of finance and the world of investing. With panelists of diverse experience through the entire value chain of finance from experienced international venture capitalists, to leading sell-side analysts to public equity fund managers, discover their views on what investors are looking for.</p> <p>Chair: Mr Lawrence Gozlan, Scientia Capital</p> <p>Panelists: Mr Andrew Goodsall, UBS Healthcare Equity Research</p> <p>Dr Sunny Sharma, Managing Director, Orbimed, India</p> <p>Dr Selena Chaisson, Director of Healthcare Investments, Bailard</p> <p>Dr David Collier, Managing Director, CMEA Capital</p>
<p>1:00pm – 2:00pm</p> <p>Lunch <i>BioIndustry Exhibition Hall</i></p>				
<p>2:00pm – 3:30pm</p> <p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p style="text-align: center;">MEDTECH</p> <p>Reimbursement Strategies for Medical Devices</p> <p>After the thrill of invention, the slog of development and innovation and the trials of Regulatory approval comes the key stage - reimbursement. Too often looked upon as a footnote, this is a complex and demanding area which is vital for the commercialisation of innovation and the survival of the innovative company.</p> <p>Chair: Dr Greg Roger, Advanced Surgical Design Manufacture</p> <p>Speakers: Dr Alan Robertson, Chief Executive Officer, Pharmaxis</p>	<p style="text-align: center;">HUMAN HEALTH</p> <p>Biomarkers in Drug Discovery and Development: Commercialisation Pathways and Strategic Partnerships</p> <p>Biomarkers of disease, genotype, and drug response are assuming an increasingly important role in drug discovery and development as well as in the transformation of medical practice. Drug developers are investing heavily in this area as validated biomarkers provide the opportunity for smarter and earlier decision making in R&D and clinical application. Further advances promise to lower the cost and time of drug development, clinical trials and regulatory approval, by pinpointing those patients most likely to benefit from new drugs and better understanding patient response.</p> <p>This session will discuss some of the most</p>	<p style="text-align: center;">AG / INDUSTRIAL / FOOD</p> <p>Food Security and AgBio</p> <p>Food security has become an important topic especially in the face of climate change. This session will explore various aspects on how biotechnology can contribute to food security in Australia and abroad.</p> <p><i>Session chair and other speakers to be confirmed</i></p> <p>Speakers: Dr Ganesh Kishore, CEO Malaysian Life Sciences Capital Fund, Burrill and Company / Malaysian Technology Development Corporation</p>	<p style="text-align: center;">INVESTMENT / BUSINESS</p> <p>Waging War on Counterfeit Pharmaceuticals: Effective Investigation and Enforcement Across Jurisdictions</p> <p>In this session the focus will be on identifying areas of industry exposure to counterfeiting, including online trade in pharmaceutical products. Tips and traps in anti-counterfeiting and IP enforcement campaigns will be discussed in addition to border control: Australian Customs and World Customs Organisation initiatives to combat trade in pharmaceutical counterfeits; how counterfeits adversely impact upon pharmaceutical businesses; anti-illicit trade strategies and trends; and best practice in investigation and</p>

	<p>Ms Sue O'Malley, Consultant Reimbursement Strategist, Medical Intelligence</p> <p>Ms Beth L Roberts, Attorney at Law, Hogan and Hartson USA</p>	<p>innovative scientific developments, promising regulatory initiatives, and strategic partnerships forging the way to successful development and commercialisation of biomarkers, as well as the challenges associated with biomarker development, such as clinical validation, reimbursement, and regulatory oversight.</p> <p>Chair: Dr Colleen Nelson, Chair, Prostate Cancer Center, Vancouver General Hospital / Translational Research Institute PAH</p> <p>Speakers: Dr Daniel Chelsky, Chief Scientific Officer, Caprion Proteomics</p> <p>Mr Rocky Ganske, CEO, Axela</p> <p>Mr Erinn Broshko, CEO, MedBioGene</p> <p><i>Sponsored by Government of Canada</i></p>		<p>enforcement initiatives.</p> <p>Chair and speaker: Ms Elisabeth White, Partner, Baker and McKenzie</p> <p>Speakers: Mr Bjorn Roberts, Director of Intelligence and Consumer Safety, Australian Customs Service.</p> <p>Mr Richard McCormack, Barrister & Solicitor, Richard McCormack & Associates</p> <p><i>Sponsored by Baker and McKenzie</i></p>
--	--	---	--	---

3:30pm – 4:00pm Afternoon Tea
BioIndustry Exhibition Hall - Sponsored by Government of Canada / Province of Manitoba

4:00pm – 5:30pm	GENERAL	HUMAN HEALTH	AG / INDUSTRIAL / FOOD	INVESTMENT / BUSINESS
<p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p>What makes the Media tick?</p> <p>Insights from industry and mainstream journalists to help delegates understand how the news cycle works</p> <p>What do the media need from Companies to get a story in the papers; i.e breaking news; access to patients ; movement in share price for a business/investment story. Why is there resistance to biotech stories from mainstream outlets and how can this be overcome?</p> <p>How can the industry help media to understand the stages of clinical trial development?</p> <p>Chair: Dr Fintan Walton, Chief Executive Officer, PharmaVentures, UK</p> <p>Speakers: Dr Karen Bernstein, BioCentury, Co-Founder, Chairman and Editor-in-Chief</p> <p>Mr Nick Evans, Editor, Biotechnologynews.net, Aspermont Ltd</p> <p>Mr Steven Edelson, Executive Editor, SciBX</p>	<p>Health Technologies; helping to solve poverty in Asia and Africa</p> <p>Developing "appropriate" technologies to meet the needs of the rural poor in Asia and Africa.</p> <p>Chair: Dr Graeme Woodrow, Chief, CSIRO Molecular and Health Technologies</p> <p>Speakers: Associate Professor Jim Black, Nossal Institute for Global Health, Melbourne University</p> <p>CSIR India speaker (name to be confirmed)</p> <p>Mahidol University, Bangkok speaker (name to be confirmed)</p>	<p>Successful Models for Building a Sustainable Future Bioeconomy</p> <p>At a time when sustainability is a mantra, agricultural and industrial biotechnology hold great hope for the development of food production, manufacturing and delivery processes that limit the depletion of scarce resources.</p> <p>The Government of Manitoba in Canada, has strategically fostered relationships with several regions in Australia, building linkages with government, policy makers, the scientific community and industry to mobilise shared resources and more quickly commercialise vital technologies.</p> <p>The session will discuss ideas and models for jointly building a sustainable bioeconomy through visionary direction from government and strategic international partnerships.</p> <p><i>Session chair to be confirmed</i></p> <p>Speakers: Mr Doug McCartney, Director - Science, Innovation & Business Development, Manitoba Govt</p>	<p>Maximising value: How tough markets are reshaping the business models of big pharma and venture capital and biotechnology companies</p> <p>Business model structuring of big pharma and venture capital organisations is facing a period of transition. The end result of this transition depends on how long this financing stagnation to initial public offerings (IPOs) of drug discovery and development companies will last. Take this opportunity to hear from those at the forefront of change in Asian-Pacific markets and learn how current economic conditions are driving values of deals and acquisitions.</p> <p>Chair: Mr Peter Sandbach, Head of Communications, Roche Pharma Partnering</p> <p>Speakers: Dr Bardia Akbari, Executive Director, Global Business Development, Roche Pharma Partnering, USA</p>

			<p>Mr Sean McKay, Managing Director, Composites Innovation Centre, Canada</p> <p>Dr. Geoff Hicks, CIHR Canada Research Chair in Functional Genomics; Director, Regenerative Medicine Program Associate Professor; Biochemistry & Medical Genetics and Physiology, University of Manitoba; Senior Investigator, Manitoba Institute of Cell Biology, CancerCare Manitoba</p> <p>Dr Lee Anne Murphy, Director, Public and Industry Affairs, Monsanto Canada</p> <p><i>Sponsored by Province of Manitoba</i></p>	<p>Dr Geoff Brooke, Managing Director and Co-founder, GBS Venture Partners</p> <p>Mr Stephen Walters, Chief Economist, J.P. Morgan</p> <p>Dr Leigh Farrell, Vice President Business Development, Biota Holdings Ltd</p>
5:30pm – 7:00pm	<p>INTERNATIONAL RECEPTION BioIndustry Exhibition Hall Welcome delivered by Mr Thomas MacDonald, Consul General of Canada Sponsored by Government of Canada / Province of Manitoba</p>			
7:00pm – 8:00pm	<p>AusBiotech 2009 Major Partners VIP Reception - <i>by invitation only</i> Melbourne Convention and Exhibition Centre</p>			

THURSDAY 29 OCTOBER

9:00am – 5:30pm	BIOINFORMATICS AUSTRALIA CONFERENCE – BA2009			
9:00am – 11:00am	<p>PLENARY 3 - Millis Oration - Sponsored by CSL <i>Presentation title to be confirmed</i> Dr Megan Clark, Chief Executive, CSIRO, Australia</p> <p>PLENARY 4 -Presentation title to be confirmed Dr Johnsee Lee, President, Industrial Technology Research Institute, Taiwan</p> <p><i>Melbourne Convention Centre</i></p>			
11:00am – 11:30am	<p>Morning Tea BioIndustry Exhibition Hall</p>			
11:30am – 1:00pm	<p>MEDTECH</p> <p>Meet the Regulators Workshop</p> <p>Practical perspective to working with a regulator as you progress your regulatory submission or audit</p> <p><i>Chair and other speaker to be confirmed</i></p> <p>Speakers: Dr Rohan Hammett, National Manager, TGA</p>	<p>HUMAN HEALTH</p> <p>Funding Opportunities to Support Biotech R&D in Infectious Disease</p> <p>This session will provide an overview of the funding opportunities available to support R&D in infectious disease. Panelists will represent both government, NGOs, and VC firms, and will provide a unique perspective on each respective approach for support of novel biotechnologies. Additionally, the proposed panelists have specific interest in Asia,</p>	<p>AG / INDUSTRIAL / FOOD</p> <p>Biotech in Australian Agricultural Cropping</p> <p>Biotechnology has been part of the Australian cropping system since the introduction of GM cotton in 1996. Following a presentation on developments in the area, a farmer will discuss his experiences with GM canola followed by a presentation on the use of GM in the horticulture industry.</p>	<p>INVESTMENT / BUSINESS</p> <p>Changing Business Models and New Financial Opportunities</p> <p>Small, early stage biotech companies are struggling to raise funding forcing them to cut costs and rethink their business models. Many are looking at earlier stage partnering, outsourced research and BD roles and convertible notes or other alternative sources of funding. A viable way forward for these biotech's</p>

	<p>Dr Adrian Oates, Vice President of Quality and Regulatory, Universal BioSensors</p>	<p>including Wellcome's recently launched "By India for India" program, PATH's strategic focus on reaching developing nations, and Kleiner Perkins Caufield and Byers investment in novel vaccine manufacturing technologies which will allow for decentralized vaccine production and increased vaccine utilization.</p> <p>Chair and Speaker: Dr Jennifer Hanneschlager, Managing Scientific Director, McKenna Long and Aldridge LLP, United States</p> <p>Dr Jane Ryan, Vice President of Product Development, Biota Holdings Ltd</p> <p>Dr Fiona MacLaughlin, Wellcome Trust, United Kingdom</p> <p>Dr Benjamin P. Chen, Managing Director, Burrill & Company, San Francisco</p>	<p>Chair: Mr Keith Glasson, General Manager, Pioneer Hi-Bred Australia</p> <p>Speakers: Dr Andrew L.D. Walter, AH and GM Walter Pty Ltd</p> <p>Dr Steve Chandler – General Manager, Florigene</p> <p>Mr David Hudson, SGA Solutions Pty Ltd</p> <p>Dr. Gary Fitt, Deputy Chief, CSIRO Entomology</p>	<p>will be discussed."</p> <p>Chair: Dr Stewart Washer, Director, AusBiotech Ltd</p> <p>Panelists: Mr Hershel Berry, Blueprint Life Sciences</p> <p>Dr Graeme Wald, Wilson HTM</p> <p>Mr David Blake, Bioshares</p> <p>Mr Lawrence Gozlan, Scientia Capital</p> <p>Mr Scott Power, ABN AMRO Morgans Limited</p> <p>Dr Elliot Parks, President and CEO, Hawaii Biotech Inc</p>
--	--	--	--	---

12:45pm – 2:00pm Ernst and Young Global Report Luncheon Melbourne Convention and Exhibition Centre

1:00pm – 2:00pm Lunch BioIndustry Exhibition Hall

2:00pm – 3:30pm	MEDTECH	HUMAN HEALTH	AG / INDUSTRIAL / FOOD	INVESTMENT / BUSINESS
<p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p>In Vitro Diagnostics: New Technologies, New Markets, New Regulations, New Risks?</p> <p>Rapid developments in technology are producing new diagnostics which offer great promise in areas ranging from population screening to personalised medicine. However these technologies bring new challenges in public health, funding and ethics and regulatory systems are evolving rapidly in response. This session looks at the challenges in developing a new IVD and the proposed new regulatory frameworks both in Australia and internationally.</p> <p>Chair: Dr Mervyn Thomas, Managing Director, Emphron Informatics</p> <p>Speakers: Dr Jenny Harry, CEO Tyrian Diagnostics</p> <p>Dr Susan Alder, Consultant, SJ Alder Pty Ltd</p> <p>Dr Arthur Brandwood, Managing Director,</p>	<p>The challenge and opportunity of targeted therapies:</p> <p>The tools of biotechnology are used to develop innovative drugs that will make a meaningful difference in the lives of patients. Application of cutting-edge science and technology is making earlier, better, more informed decisions in its development of therapeutics.</p> <p>Treatment, prevention and detection will be guided by the use of more effective "biomarkers". New biomarkers that help to monitor therapy, and serve to identify and select patients that are more likely to respond, are a focus of current efforts. However the best way to integrate these approaches into clinical and regulatory strategies continues to evolve.</p> <p>Chair: Mr Ian Thompson, Managing Director, Amgen</p> <p><i>Other speakers to be confirmed</i></p> <p>Dr C. Glenn Begley, Vice President, Hematology Oncology Research, Amgen</p>	<p>Biofuels</p> <p>While the biofuels industry in Australia is still in its relative infancy, growth in the sector is rapidly gaining momentum. Australian governments are increasingly recognising the need to encourage and support research and development of biofuels manufactured from non-food sources that will achieve sustainable long term benefits to the environment and the Australian community. This session will provide an overview of Australia's capabilities in the development and commercialisation of second generation biofuels, with a focus on research activities directed at delivering commercial outcomes from renewable resources, as well as an end-user's perspective of the industry.</p> <p>Chair: Dr Les A Edye, Principal Research Fellow, Biofuels & Biorefineries, Queensland University of Technology</p> <p>Speakers: Dr Tom Beer, President, IUGG, Leader -</p>	<p>Valuing and Commercialising Intellectual Property</p> <p>The valuation and commercialization of Intellectual Property is difficult at the best of times, particularly where there are long paths to market. The Global Financial Crisis has added salt to the wounds. This session will examine valuation and commercialization of IP from three different view points:</p> <ul style="list-style-type: none"> - A financial valuer; - A solicitor dealing with licensing and commercialization ; and - A biotech investor <p>Chair and speaker: Mr Peter Francis, Partner, Francis Abourizk Lightowlers</p> <p>Speakers: Mr Hamish Blair, Senior Adviser, Leadenhall VRG</p> <p>Dr Andrew Kelly, Executive Director, BioPacificVentures, New Zealand</p>

	<p>Brandwood Biomedical Pty Ltd</p> <p><i>Sponsored Brandwood Biomedical</i></p>	<p><i>Sponsored by AMGEN</i></p>	<p>TYPE Hazards Theme, Transport Biofuels Stream Leader, Energy Transformed Flagship, CSIRO</p> <p>Mr Ian O'Hara - Senior Research Scientist, Centre for Tropical Crops and Biocommodities, QUT</p> <p>Mr Brad Wheatley, Research Leader, Environment, Boeing Australia</p> <p><i>Sponsored by NCRIS</i></p>	
--	--	----------------------------------	--	--

3:30pm – 4:00pm **Afternoon Tea**
BioIndustry Exhibition Hall

<p>4:00pm – 5:30pm</p> <p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p>GENERAL</p> <p><i>International linkages</i></p> <p>Chair: Dr Anna Lavelle, CEO, AusBiotech</p> <p><i>Other speakers to be confirmed</i></p> <p>Speakers:</p> <p>Dr Zeqi Zhou, Vice President Tianjin International Joint Academy of Biotechnology and Medicine(TJAB), Korea</p> <p>Dr. Ca Tran Ngoc, Deputy Director, National Institute for S&T Policy and Strategy, Ministry of Science and Technology & Director, Secretariat, National Council for S&T Policy, Vietnam</p> <p><i>Sponsored by BioNet Asia Pacific</i></p>	<p>GENERAL</p> <p>Careers Catwalk</p> <p>The AusBiotech 2009 Conference 'Careers Catwalk' will showcase a variety of positions available within the field of biotechnology and will include presentations by inspirational figureheads holding diverse positions within the sector. It will also provide the opportunity for students to put their questions to key professionals within the industry as well as increase their knowledge of career options and pathways.</p> <p>Chair: Mr Andrew Macdonald, CEO, Cytopia Ltd</p> <p>Speakers:</p> <p>Dr Leigh Farrell, Vice President Business Development, Biota Holdings Ltd</p> <p>Dr Stella Clark, CEO, The Bio21 Cluster</p> <p>Ms Sue MacLeman, CEO, Benitec Ltd</p>	<p>HUMAN HEALTH</p> <p>Product Development and Regulatory Aspects in Asia Pacific</p> <p>This session will address how the regulatory agencies in Japan, Korea and Australia have responded to the biopharmaceutical industry's interest to expand the number of clinical trials in the Asia-Pacific region and how these changes are viewed by other agencies. In addition, the acceptability of foreign clinical data from trials involving biotech compounds will be discussed.</p> <p>Chair: Dr Christopher J. Holloway, CSO, ERA Consulting Ltd, United Kingdom</p> <p>Speakers:</p> <p>Ms Ana Maria Moreno, Research Associate, Corelli Consulting</p> <p>Dr Dianne Jackson-Matthews, ERA Consulting, Australia</p> <p>Dr Zaheer Anjum, Acting Head, Office of Prescription Medicines, TGA</p>	<p>AG / INDUSTRIAL / FOOD</p> <p>Biosecurity</p> <p>Like many island nations, Australia is constantly exposed to plant and animal diseases through trade. As both inbound and outbound trade increases, the likelihood of disease outbreaks will also increase. This session provides an overview of biosecurity issues in Australia, with a focus on plant and animal diseases, the contribution that biotechnology is making in protecting the Australian environment and how some of these technologies are commercialised.</p> <p>Chair: Professor John Lovett, Chairman, Cooperative Research Centre for National Plant Biosecurity</p> <p>Speakers:</p> <p>Professor Tony Peacock, CEO, Invasive Animals CRC</p> <p>Dr Robyn Lindner, CSO, Tyrian Diagnostics</p> <p>Mr Andrew Geering, Principal Plant Pathologist, Industry Services Queensland Primary Industries and Fisheries</p> <p><i>Sponsored by CRC for Centre for National Plant Biosecurity</i></p>	<p>INVESTMENT / BUSINESS</p> <p>Global Regulatory Challenges and Opportunities</p> <p>Global regulatory challenges require a consistent and integrated approach to biotechnology products, with regional considerations. Sponsors are exploring the promises and opportunities available in the Asian Pacific region. This session will bring together a TGA official, consultants and corporate experts for an overview of challenges and opportunities of these programs.</p> <p>Chair: Dr Rohan Hammett, National Manager, TGA</p> <p>Speakers:</p> <p>Dr Victoria Elegant, Vice-President, Asia-Pacific, Regulatory Affairs / Pharmacovigilance, Baxter Healthcare Corporation, Inc., Shanghai, China</p> <p>Dr Evan Siegel, President and CEO, Ground Zero Pharmaceuticals, USA.</p> <p>Dr Jillian Bennett, Director, Regulatory Affairs, CSL</p>
--	--	---	--	---	--

		Dr Danielle Smith Project Manager Medicines Development Ltd			
4:00pm – 5:30pm	AUSBIOTECH 2009 TRADE AFTERNOON <i>BioIndustry Exhibition Hall</i> The AusBiotech BioIndustry Exhibition is the largest biotechnology exhibition assembled in Australia. The exhibition showcases the latest in business and product services, equipment, instrumentation, devices and state-of-the-art technology. The Trade Afternoon is offered in addition to general access of the BioIndustry Exhibition for exhibitors and delegates. This time has been allocated specifically for exhibitors to invite guests and for graduate and undergraduate students to attend and engage with industry.				
7:00pm – 11:30pm	AUSBIOTECH 2009 CONFERENCE DINNER <i>Melbourne Convention and Exhibition Centre</i> Sponsored by Pfizer				

FRIDAY 30 OCTOBER

9:00am – 1:00pm	BIOINFORMATICS AUSTRALIA CONFERENCE – BA2009			
9:00am – 9:30am	PLENARY 4 – ‘Making sense of impending tax changes’ Mr Sergio Duchini, Partner & National Leader R&D Taxes & Incentives/Co. Director, Deloitte Ms Sandra Buth, Principal, Global Employer Services/Reward, Deloitte Chaired by Dr Anna Lavelle, CEO, AusBiotech, Ltd <i>Melbourne Convention Centre – Concurrent Session Room – Level 2</i>			
9:30am – 11:00am	GENERAL Thriving and surviving in these economic times - an international perspective Whilst the current global financial crisis presents a level of uncertainty, it also offers opportunities that should be maximised to ensure future growth. Our team of speakers (both with corporate and intellectual property experience) will provide an international perspective on the key challenges faced by the industry and some of the strategies that should be implemented to leverage opportunities and minimise risk. Chair: Mr Tony Conaghan, Practice Group Leader, Intellectual Property and Technology Practice, DLA Phillips Fox, Australia Speakers: Dr Lisa A. Haile, J.D., Partner, Life Sciences Practice, DLA Piper, United States Mr Sajai Singh, Resident Partner, J.Sagar	HUMAN HEALTH Making your company attractive to big pharma – marriage or rejection! Chair and Speaker: Dr Greg Wiederrecht, Vice President and Head, External Scientific Affairs, Merck Sharp and Dohme Speakers: Dr Mark Heffernan, CEO, OPSONA Therapeutics Ltd Dr Deborah Rathjen, CEO and Managing Director, Bionomics Limited <i>Sponsored by Merck Sharpe and Dohme</i>	AG / INDUSTRIAL / FOOD CleanTech The focus of this session will be on how advanced biological systems and novel biomaterials can be applied across a range of industries to deliver environmental outcomes. The session will provide an overview of what technologies are available, detail of some of the technologies, how they can deliver improvements to industrial processes, resource efficiencies and the remediation of land, air and water environments, including the commercialisation of the technology or process. <i>Session chair to be confirmed</i> Mr Geoff Bell, CEO, Microbiogen Mr Jeffrey Castellias, CEO, Clean Technology AustralAsia Pty Ltd	INVESTMENT / BUSINESS Licensing / Strategic Deal Terms Chair: Mr Ian Edvalson, Partner, Wilson Sonsini Goodrich and Rosati, California, United States Speakers: Mr Ralph Villiger, Partner, Avance, Basel, Switzerland Mr Lubor Gaal, Head of Europe Search, Strategic Transactions Group, Bristol-Myers Squibb Ms Sarah Terry, Global Managing Director, Life Science Analytics, MEDTRACK
Concurrent Sessions: Level 2 Melbourne Convention Centre				

	<p>Associates, India</p> <p>Dr Charlie Day, Chief Executive Officer, Melbourne Ventures Ltd</p> <p><i>Sponsored by DLA Phillips Fox</i></p>		<p>Professor Tony Wong, Principal, Melbourne Honorary Professor, Monash University EDAW AECOM</p> <p>Baker and McKenzie Speaker (name to be confirmed)</p> <p><i>Sponsored by Victorian Government</i></p>	
<p>11:00am – 11:30am Morning Tea BioIndustry Exhibition Hall</p>				
<p>11:30am – 1:00pm</p> <p>Concurrent Sessions: Level 2 Melbourne Convention Centre</p>	<p>MEDTECH</p> <p>Creating Product Excitement – Can you develop the next must-have medtech?</p> <p>When launching a product or service into the healthcare market, evaluating your strategic links with the supply chain is critical for success in a highly demanding business environment</p> <p>Developing products is more than just engineering and science: it includes observation, creativity and refinement to develop your brand identity, generate awareness and build excitement for years to come. Getting your company out there and building its reputation is essential to differentiate you from competitors.</p> <p>Chair: Mr Richard Walmsley, CEO, Ingeneus</p> <p><i>Other speaker to be confirmed</i></p> <p>Speakers: Mr Trevor Choy, Founder, Choy Lawyers</p> <p>Mr Grant Davidson, Managing Director, Davidson</p> <p><i>Sponsored by Design Victoria</i></p>	<p>HUMAN HEALTH</p> <p>Clinical Trials</p> <p>The inaugural survey of investigator perceptions on the value of industry funded clinical research and the benchmarking survey of industry sponsored clinical research in Australia.</p> <p><i>Session chair and speakers to be confirmed</i></p> <p><i>Sponsored by NSW DSRD</i></p>	<p>AG / INDUSTRIAL / FOOD</p> <p>Taking functional foods to market</p> <p>The interest in functional foods is increasing. With the FDA recently calling a fortified breakfast cereal a drug, how can foods with beneficial health outcomes be commercialised without stepping over the line. This session will look at some foods in development, review foods that have been commercialised and look at where functional foods are headed next.</p> <p>Chair: Mr Peter R. Schutz, Chief Executive, George Weston Technologies</p> <p>Speakers: Dr Ross Crittenden, Food Science Australia and Murray Golburn Cooperative Co. Limited</p> <p>Dr Ebenezer Satyaraj, Senior Research Scientist, Nestle Research Center, St. Louis, MO, USA</p> <p>Dr Bruce Lee, Director, Food Future Flagship, CSIRO</p>	<p>INVESTMENT / BUSINESS</p> <p>Effective Means of Commercialising in India and China</p> <p>The session will have wide coverage including researcher collaborations, seeking commercial investment, pharma partnering and IP strategy. The research section will focus on CSIRO's experience through the Australian India Biotech Partnership and student exchanges with China. Pharma will be represented by a regional BD person or, if travel does not permit, one of their local counterparts. We are seeking a venture or industry incubator that invests in Asia. Griffith Hack will present on China specific collaboration and potential IP pitfalls.</p> <p>Chair: Ms Kiara Bechta-Metti, Commercialisation Manager, CSIRO</p> <p>Speakers: Dr Gangfeng Xu, Assistant Vice President, Head of Licensing and Business Development, Asia-Pacific, Wyeth Pharmaceuticals</p> <p>Mr Robert Wulff, Principal, Griffith Hack</p> <p>Dr Phil Kearney, Licensing & External Research, Merck, Sharpe and Dohme.</p>
<p>1:00pm – 2:30pm AUSBIOTECH 2009 CLOSING RECEPTION (incorporating lunch) BioIndustry Exhibition Hall</p>				
<p>2:30pm – 3:30pm</p>	<p>AusBiotech Ltd Annual General Meeting <i>Melbourne Convention and Exhibition Centre</i> All AusBiotech members are encouraged to attend and participate at the Annual General Meeting</p>			